Lupin stock: Lupin appoints Brian Savage. November 3 results test Lupin stock
Published on 10/24/2026 at 02:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCorporate dates and operating scale
- Lupin appointed Brian Savage as chief legal officer on October 22, 2026.
- Revenue reached INR 82.77 billion in the first quarter of fiscal 2027, up 10.70 percent from the prior quarter.
- Lupin's market capitalization stood at INR 880.2 billion as of October 23, 2026.
Lupin (ISIN INE326A01037) appointed Brian Savage as President and Chief Legal Officer effective October 22, 2026, according to Lupin. Savage will lead the company's global legal, compliance and intellectual property functions from New Jersey.
Revenue sets the operating base
Lupin generated INR 82.77 billion in revenue during the first quarter of fiscal 2027, an increase of 10.70 percent from the prior quarter, according to StockFin.ai. Net income was INR 14.15 billion in that period, compared with INR 14.60 billion in the fourth quarter of fiscal 2026, a decline of 3.10 percent.
The revenue increase gives the next results release a clear test: whether sales growth can offset the recent quarter-to-quarter decline in net income. Lupin operates across branded and generic medicines, complex generics, biotechnology products and active pharmaceutical ingredients.
Three dates mark the recent sequence
On September 28, 2026, Lupin received one tentative U.S. FDA approval for an apixaban oral suspension, as reported by StockFin.ai. On October 19, 2026, the company announced one board meeting to approve results for the quarter and half-year ended September 30, 2026, according to StockFin.ai. On October 22, 2026, Savage became the company's new chief legal officer.
What does the next quarter mean?
The upcoming reporting cycle will connect the growth figure with profitability. The first-quarter operating margin was 24.10 percent, down from 27.30 percent in the fourth quarter of fiscal 2026, while net income declined 3.10 percent between those periods, according to StockFin.ai.
Results dates are already scheduled
Lupin's board is scheduled to consider the quarterly and half-year results on November 3, 2026, and the company has scheduled its earnings call for November 4, 2026, according to StockFin.ai.
Market value adds scale
Lupin's market capitalization stood at INR 880.2 billion as of October 23, 2026. The company was listed on the NSE and BSE, with its healthcare and specialty pharmaceuticals profile making the November reporting dates the next concrete operating milestones.
Lupin stock facts
- Company: Lupin Limited
- ISIN: INE326A01037
- Ticker: LUPIN
- Primary exchanges: NSE and BSE
- Market capitalization: INR 880.2 billion (as of October 23, 2026)
- 52-week range: INR 1,892.90-2,529.50 (as of October 23, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
Market context: Market report BSE Sensex.
